Great business, wrong price. Don't chase it here; trim if you own it. Veeva is one of the best-run software franchises in the market: ~30% GAAP operating margins, $7.2B of cash, no financial debt, and a near-monopoly on regulated content in pharma. None of that is the question. The question is what you pay. At $286, you are paying $40.2B for the operating business. That works out to ~45x after-tax, R&D-adjusted operating income. My base case gives Veeva its guided ~15% growth fading to 3% and lets margins expand to 36% on an SBC-burdened, R&D-adjusted basis, about where management's 45% non-GAAP goal lands once stock comp is counted. That base is worth $162. Even the bull case ($229: 17% growth, 40% margin, 25% terminal ROIC) is 20% below the price.
The stock has round-tripped from fear to hope. VEEV hit a 10-year low of $148 in April on three worries. It lost four top-10 pharma CRM accounts to Salesforce. AI threatened seat-based pricing. And its 2030 targets looked out of reach. Since then it has put up two strong beats. Q2 revenue was $928M (+18%). FY27 guidance went up to $3.685B, and non-GAAP operating income to $1.64B. Management called it its "best CRM quarter ever" (12 top-20 Vault CRM commitments, three more top-20 wins in August). The stock is up 93% off the low. That recovery is real, but the price now assumes it will keep compounding. To justify $286 on the base margin path, you need 26% growth for five years, before the fade. With a 45% margin, you still need 21%. Guidance is 15%.
What the market is really doing is using a 2021 discount rate. Holding my operating story fixed, the price implies a 6.7% cost of capital. The 10-year is at 5.24% and the 30-year is at its highest since 2002. That leaves an equity-risk premium of about 1.4 points on a beta-1 software stock. Only the WACC and growth bars in the tornado move value more than ±$20. Neither gets you close to the price, and the WACC bar is the one the bond market controls.
The call: No new money above ~$200. Accumulation zone is $165–175, around the probability-weighted value, and a full position makes sense below ~$150. It traded at $148 just six months ago. If you hold it, trim at least a third into this strength. Next catalyst is Q3 earnings on Nov 19 (EPS est. $2.21). This is a quality compounder with $44/share of net cash and a $1.4B buyback authorization remaining, so it is a sell-rich name, not a short. If you want to express the view, use a defined-risk bear call spread above the $310 52-week high, not naked exposure.
Risk Profile — Medium (business) / High (valuation)
HIGHDuration / rates: 57% of value is terminal. With 30-year yields at a 24-year high, ±100bp of WACC = $145–$183. Long duration, short rates.
HIGHCRM franchise erosion: Commercial Cloud subscription is ~$1.4B of ~$3.1B FY27 subscription. The legacy Salesforce-platform CRM contract runs off by 2030. Four top-10 pharmas left for Salesforce Life Sciences Cloud; 12 top-20s committed to Vault CRM. Loss of the next wave would hit growth and margin at the same time.
MEDAI vs seat pricing: Pharma field forces and MLR/regulatory headcount are what Veeva charges per seat for. Veeva AI / Falcon agents (first go-lives late 2026) are Veeva's answer, but monetization is undisclosed. Agentic labor could shrink the seat base faster than agent revenue replaces it.
MEDStock-based comp: $495M TTM (14% of revenue). That is the gap between the 44% non-GAAP margin the Street quotes and the ~30% GAAP margin. It is modeled here as a real cost. Buybacks ($756M TTM) mostly offset the dilution, but they use cash that is otherwise counted in value.
LOWEnd-market / FX: Customers are pharma R&D and commercial budgets (drug-pricing policy, big-pharma M&A consolidation). About 40% of revenue is outside North America. There is no commodity exposure and inventory is nil. The "inventory" is the installed seat base plus the $1.3B deferred-revenue float.
Scenarios
Bear (25%)
11% growth, fading 1.5pp/yr; CRM share loss continues; 31% margin; S2C 2.0; beta 1.2; g 2.5%, ROIC 15%
17% growth (hits ~$6B by FY30), Vault CRM wins the migration, AI monetizes; 40% margin; S2C 4; beta 1.0; g 3.5%, ROIC 25%
$229
Revenue & GAAP EBIT ($M, margin)
■ Revenue ■ GAAP operating income · label = GAAP EBIT margin. The FY23–24 margin dip came from the SBC step-up and investment in Vault CRM/clinical. FY26 includes a ~$31M Q2 charge (XBRL $195.9M vs $226.5M reported by aggregators).
Driver tornado — value/share
No single lever reaches $286. The widest bars are the discount rate and near-term growth. Margin matters less than you'd think because Veeva is already near its mature margin, and the capital-light model makes the reinvestment assumption (S2C) nearly irrelevant.
Sensitivity — WACC × terminal growth
WACC ↓ / Terminal g →
2.5%
3.0%
3.5%
4.0%
7%
$249
$268
$292
$326
8%
$207
$217
$230
$247
9%
$179
$185
$193
$202
10%
$158
$163
$167
$173
11%
$143
$146
$149
$153
Base story (14%→10% growth, 36% adj. margin). Base WACC 10.1% → 9.6% stable. Color = vs $285.87: red ≤−15%, pink −15..−5, grey ±5, green >+5.
Sensitivity — growth × margin (the operating story)
Even 18% growth at a 48% SBC-burdened margin does not reach the price at a 10% WACC. Color = vs $285.87: red ≤−15%, pink −15..−5, grey ±5, green >+5.
Normalization & R&D converter ($M)
TTM revenue (Q3 FY26–Q2 FY27)
3,458.1
TTM GAAP operating income (margin)
1,034.9 (29.9%)
5-yr avg GAAP EBIT margin FY22–26
24.1%
R&D: TTM / FY26 / FY25 / FY24
821.9 / 767.4 / 693.1 / 629.0
Research asset (3-yr SL life)
1,564.5
Current-year amortization
696.5
R&D-adjusted EBIT (margin)
1,160.3 (33.6%)
Invested capital (equity + leases − cash + research asset)
1,904
After-tax ROIC (R&D-adjusted)
47%
Normalize = No. Veeva is a secular, not cyclical, business. The 5-yr average (24%) would understate a margin that is structurally expanding, so the model uses TTM and fades to target. SBC stays in EBIT (Damodaran). Interest income on the $7.2B cash pile (~$290M/yr pre-tax) is excluded from EBIT, and the cash is added to value instead.
Yr1 FCFF $836M vs TTM SBC-adjusted unlevered FCF ≈ $920M (OCF $1,665M − after-tax interest ~$223M − capex $27M − SBC $495M). The model is not starving the base year. Terminal: g 3.0%, ROIC 20%, reinvestment 15% of NOPAT.
Bridge ($M)
PV of FCFF, years 1–10
8,528
PV of terminal value (57% of operating value)
11,173
Value of operating assets
19,700
+ Cash & short-term investments (7/31/26)
7,243
− Debt (operating lease liabilities)
(152)
Equity value
26,792
÷ Diluted shares (161.8M basic + options/RSUs)
165.5M
Value per share
$161.88
Market cross-check
Street: 22 Buy / 9 Hold / 1 Sell; mean PT $297 (range $180–343)
+4% to mean
Morgan Stanley upgrade at the Feb low (EV/FCF at 10-yr low)
EV / TTM FCF (SBC added back, as reported) / FCF ex-SBC
28x / 44x
52-week range
$148.05 – $310.50
The Street is anchored on non-GAAP earnings (SBC excluded) and a lower discount rate. That accounts for the whole gap between the $297 consensus and this $162.
Reality checks
Stable WACC 9.6% > terminal g 3.0% (< Rf 5.24%)
PASS
Terminal share of value 57% (flag >70%)
PASS
Base-year FCFF vs actual SBC-adjusted FCF ($836M vs ~$920M)
PASS (conservative)
Base revenue in FY30 (~$5.3B) vs old $6B goal
below goal; bull hits it
Target margin 36% vs mgmt 45% non-GAAP less ~13% SBC + ~3.5pp R&D adj.